World Journal of Advanced Research and Reviews
eISSN: 2581-9615 CODEN (USA): WJARAI
Cross Ref DOI: 10.30574/wjarr
Journal homepage: https://wjarr.com/

(REVIEW ARTICLE)

Check for updates

Stimulating Economic Growth and Innovations by Leveraging Bioinformatics in Biotechnology SMEs

Jide Adedamola Afolabi [1,*], George Sarkodie Opoku [2] and Victor Apatu [3]

[1] *Department of Information Systems, Analytics and Operations, College of Business, University of Louisville, Kentucky, United States of America*
[2] *Department of Mathematics, College of Arts and Sciences, Illinois State University, Illinois, United States of America.*
[3] *Department of Mathematical Science, College of Sciences and Arts, Michigan Technological University, Michigan, United States of America.*

World Journal of Advanced Research and Reviews, 2024, 23(02), 211–221

Publication history: Received on 17 June 2024; revised on 28 July 2024; accepted on 31 July 2024

Article DOI: https://doi.org/10.30574/wjarr.2024.23.2.2257

Abstract

Biotechnology is an emerging field. It can foster economic expansion through scientific advancements. Small and Medium-Sized Enterprises (SMEs) are integral in this perspective as Biotechnology SMEs strongly support innovation and agility. This article elaborates on the role of bioinformatics as it is a pivotal element of biotechnology. It helps SMEs to analyze biological data using computational tools, which foster their economy and make them successful. This study has thrown light on core ideas of biotechnology and bioinformatics, investigated the distinctive position of SMEs, and unfolded the challenges they face, and the economic impacts. The study analyzes case studies to demonstrate how SMEs can increase their productivity and innovation by incorporating bioinformatics into their operations. Moreover, this study shed light on challenges, opportunities, and future trends in adopting bioinformatics. This article aims to address how small and medium-sized biotech businesses might strategically use bioinformatics for innovation and to promote economic growth.

Keywords: Bioinformatics; SMEs; Biotechnology; Economic Growth; Innovation

1. Introduction

The field of biotechnology is the intersection of biology and technology. It has prospects for scientific advancement and economic growth so it is evolving at a fast pace (Khan, 2020). This field has various volunteers particularly Small and Medium Enterprises (SMEs). The Small and Medium Enterprises (SMEs) are bringing innovation and agility to biotechnology (Cherchem & Keen, 2022). Despite this, the limited resources of SMEs and strong competition are making the situation challenging for them (Coghlan et al., 2020). At this point, bioinformatics comes into play. Bioinformatics which is a combination of biology and information technology analyzes biological data utilizing computational technology (Gahlawat et al., 2023).

Extensive data obtained from modern biological research can be managed easily by various bioinformatics tools and procedures, so it has transformed biotechnology completely. Moreover, biological processes become completely comprehensible because of bioinformatics. It also plays the role of the founding stone of various products and services (Mahalakshmi et al., 2022). As Bioinformatics is of immense value, SMEs can utilize it to improve their research and development, optimize their procedures, and compete with others in the marketplace.

* Corresponding author: Jide Afolabi

This article explains the ideas of biotechnology and bioinformatics, throws light on the importance of SMEs in the biotechnology landscape, and investigates the junction of biotechnology, bioinformatics, and SMEs. Moreover, case studies explain that businesses can flourish by strategically leveraging bioinformatics, which promotes economic growth.

2. Understanding Biotechnology

Biotechnology is a multi-disciplinary applied branch of biological science that uses living organisms, cells and molecules to innovate products, which are indispensable for the betterment of human life and for conserving the environment. It covers many domains such as genetic engineering, molecular biology, biochemistry and microbiology (Demirer et al., 2021; Outeiral et al., 2021; Poblete-Castro et al., 2020). The application of biotechnology is related to fields like Healthcare, Crop Production & Agriculture, Environmental Management and Industrial Processes (Maurya et al., 2021).

Genetic engineering is a major area of biotechnology. It modifies the DNA of an organism to attain desired characteristics. Medicine has made significant advancements because of this technology. Various gene therapies and personalized medicine illustrate this advancement. Genetic engineering has produced genetically modified crops as well. Such crops have desired characteristics like resistance to environmental stresses, pests, and diseases. In turn, they enhance the yield and security of food (Nicholl, 2023).



Figure 1 Genetic Engineering (Morohoshi & Komamine, 2001)

Biopharmaceuticals is one more pivotal side of biotechnology. It forms drugs and vaccines with the help of biological molecules and procedures. It has progressed due to progressions in understanding human biology and disease flow mechanisms. Unlike traditional pharmaceuticals, biopharmaceuticals give targeted treatments with very little side effects (Rosales-Mendoza et al., 2020).

Lastly, white biotechnology or Industrial biotechnology generates chemicals, materials, and energy from renewable resources utilizing enzymes and microorganisms. This technology decreases fossil fuel dependence, lessens negative environmental influence and supports sustainability (Zeng et al., 2020).

2.1. Small and Medium-Sized Enterprises (SMEs) in Biotechnology

SMEs are agile. Their sizes are small and resources are limited. In biotechnology, SMEs place attention on specialized areas of research and development. Because of this, they innovate speedily, alter as per emerging market demands, strengthen the economy, and play a major role in the field.

However, in the field of biotechnology, various challenges are encountered by SMEs. Firstly, their ability to carry out research and development is restricted due to their limited resources. Secondly, their entry and growth are restricted because of various regulatory policies and expensive advanced technologies. SMEs have a creative, flexible and collaborative nature so regardless of the challenges, they continue to flourish (Bloem & Salimi, 2023).

Fortunately, SMEs are confronted by new opportunities to tackle these challenges using bioinformatics in recent years and boosting their competitiveness. Bioinformatics tools and technologies facilitate process efficiency for SMEs, creating cost reductions in research, and resulting in quicker pathways to product development (Wong et al., 2020).

3. The Role of Bioinformatics in Biotechnology

Bioinformatics is the management of biological data and its analysis using computational technology. It comprehends complex biological systems by utilizing tools and procedure developed by uniting biology, computer, and mathematics. Bioinformatics has become very important for modern biotechnology. It helps researchers interpret the bulk of data. For example, data generated by high-throughput technologies like next-generation sequencing and mass spectrometry can be easily interpreted by researchers using Bioinformatics tools and procedures (Saeed et al., 2020).



Figure 2 Bioinformatics (NHS)

Some important tools and procedures of bioinformatics are structural biology tools, sequence alignment algorithms, data mining techniques, and genome annotation software. They help in protein structures envisage, comprehension of disease-related genetic variations, gene identification and roles of identified genes etc. (Lakshmi & Ramyachitra, 2020).

3.1. Bioinformatics is very important in various areas of Biotechnology



Figure 3 Personalized Medicine (PRESSBOOKS)

Genomic Research: Bioinformatics is very important in helping to analyze large amounts of genomic information, find genes and sequences, and study their functions. It allows the researcher to identify the cause or predisposing genes for diseases, identify disease markers, and create therapeutic interventions (Fernandez-Pozo et al., 2022).

Drug Discovery: Substantial evidence has it that bioinformatics as a tool enhances the techniques used in drug discovery by pointing out probable drug targets, or drug interactions, and improving the characteristics of drug candidates. It is useful in compound filtering, active molecule binding, and cheminformatics; this is important since it speeds up the process of drug discovery, and development as compared to traditional approaches (Sharma et al., 2023).

Personalized Medicine: Bioinformatics help in creation of personalized medicines after mapping the distinct genetic marks for disease risk, as well as the reaction to treatments. This enables specific treatments that are more effective than the general ones that come with many side effects (Branco & Choupina, 2021).

Synthetic Biology: Bioinformatics help in the architecting and assembling of synthetic biology systems. It allows for the construction and analysis of metabolic routes, the behavior of genes, and the regulation of networks, the manipulation of which can lead to the creation of organisms possessing desirable characteristics (Tan et al., 2021).

4. Leveraging Bioinformatics for SME Success

SMEs harnessing bioinformatics in biotechnology can have breakthroughs in research and development, process optimization, and market rivalry dynamics. A few schemes for unifying SME practices and Bioinformatics are:

Partnership arrangements: SMEs can have proficiency and resources of bioinformatics by joining forces with conglomerates, academic institutions, and research facilities. Such collaborations are sources of boosted innovation, informative viewpoints, and curtailed costs (Wu, 2020).

Emphasis on Training and Education: Training and education of the employees in bioinformatics can bring improvements to the company and can improve the knowledge of SMEs to use bioinformatics tools and technologies (Attwood et al., 2019).

Adoption of Cloud-Based Solutions: Web-based bioinformatics platforms provide efficient and the best solutions to the issues of huge data storage and sharing. Thus, the provided platforms may help SMEs optimize their routines and avoid significant inefficiencies (Kumar et al., 2022).

Utilizing Open-Source Tools: There are plenty of unrestricted bioinformatics tools and databases that can be utilized by SMEs to carry out research and analysis. In this way they can have competitive leverage there is no need for them to spend large amounts (Kim, 2022).

5. Case Studies of Successful Integration

5.1. Case Study 1: Ginkgo Bio works

A Small and Medium-Sized Enterprise based in Boston, Ginkgo Bioworks has been one such example that took advantage of bioinformatics in the transformation of synthetic biology. Ginkgo Bioworks, founded in 2008 designs custom microbes for use across industries including pharmaceuticals, and agriculture as well as industrial chemicals. The peculiar strategy of Ginkgo Bioworks unifies sophisticated bioinformatics tools, genome analysis, machine learning, and high-throughput screening to expedite the engineering cycle of engineered organisms (Lord, 2018).

5.1.1. Key Strategies and Tools

Automated Foundry: The automated foundry of Ginkgo carries out large-scale assembly and testing of engineered organisms by leveraging an efficient system of robotics. State-of-the-art algorithms of bioinformatics compelled this automation. Bioinformatics algorithms speedily find successful genetic modifications by analyzing experimental data (Levine, 2021).

Machine Learning Integration: At Ginkgo, vast amounts of genomic data are analyzed with the help of Machine learning models to find genetic modification results. These findings help in the construction of new organisms to avoid time-consuming experimentations like the old-fashioned brute force method (Kirshner, 2020).

Partnerships and Collaborations: As for the partnerships, Ginkgo Bioworks is working with several industry giants and research laboratories, improving the company's bioinformatics and widening the range of its uses. Some examples are the venture with the Bayer company in microbial solutions for agriculture (Waltz, 2023) and with Roche on enzyme advancement for pharmaceuticals (Dutton, 2021).

5.1.2. Impact and Achievements

Market Success: Ginkgo's dependence on bioinformatics for engineering has resulted in the development of new products like; tailored yeast strains used in the production of cultured notes for scent and taste, and microbes that synthesize cannabinoids for medical use (Moderator: et al., 2016).

Expansion and Growth: It has expanded tremendously by raising millions in funding and inked deals with large organizations. By looking at the case of Ginkgo, one can conclude that bioinformatics can be a source of significant change in synthetic biology.

5.2. Case Study 2: Moderna Therapeutics

SME, Moderna Therapeutics, located in Cambridge, Massachusetts was established in 2010 (Iansiti et al., 2020). It has established mRNA-based therapies and vaccines by leveraging Bioinformatics. The Innovative approach of Moderna instructs cells by messenger RNA to generate proteins. It can either deter or address diseases (TENPENNY).

5.2.1. Key Strategies and Tools

mRNA Design Platform: mRNA sequences are rapidly analyzed and designed by the bioinformatics platform of Moderna. This platform embeds sophisticated algorithms which anticipate the response of mRNA sequences in human cells, thereby guaranteeing efficient production of protein (Daniel et al., 2022).

High-Throughput Screening: High-throughput screening methodologies allow Moderna to screen thousands of mRNA constructs cheaply at a rapid pace. The data obtained is then further analyzed by bioinformatics tools to select the most potential hits for further development (Rasmussen et al., 2024).

Cloud Computing: The firm uses Cloud Computing Services in addressing and storing complex data, thus providing the ability to undertake multiple cycles of optimization of the mRNA sequences (Iansiti et al., 2020).

5.2.2. Impact and Achievements

COVID-19 Vaccine Development: Moderna's bioinformatics play a role in the fast delivery of the COVID-19 mRNA vaccine. Through effective assimilation of bioinformatics in their R & D agenda, Moderna developed and tested its vaccines and secured the EUA within one year of the pandemic's outbreak (Noor, 2021).

Pipeline Expansion: In addition to COVID-19, Moderna's bioinformatics-based platform has allowed the creation of a diverse pipeline of mRNA medicines for different regions and viruses, cancer, and rare genetic diseases (Barbier et al., 2022).

5.3. Case Study 3: Zymergen

Zymergen - a biotech startup, targeted at industrial applications, where bioinformatics is used to design microbes in producing commodity and specialty chemicals and materials. Established in 2013 and based in Emeryville, California, Zymergen utilizes a methodology where it combines genomic data analytics with machine learning as well as automation methods to engineer microbial strains for specific industrial applications (Si & Zhao, 2016).

5.3.1. Key Strategies and Tools

Bioinformatics Platform: The bioinformatics platform of Zymergen generates detailed microbial metabolism models by uniting genomic data from numerous resources. These models have the potential to direct the genetic engineering of microbes to improve production efficiency and productivity (Sarkar, 2021).

Machine Learning: The company analyzes experimental data utilizing the algorithm of machine learning and anticipates the influence of genetic changes on the behaviour of microbes. These predictions help in the engineering of enhanced and efficient microbial strains which can carry out the desired reactions more efficiently (CrISPr-based).

Automated Laboratory: The automated laboratory of the company carries out genetic modifications and screenings efficiently, so in turn strain development occurs speedily (Sarkar, 2021).

5.3.2. Impact and Achievements

Sustainable Production Processes: The company has established microbes that sustainably give rise to specialty chemicals, polymers, and other materials. For instance, the company has established microbes to produce sustainable bio-based adhesives and films (Mathias et al., 2016).

Commercial Success: The company's innovations have captivated significant investment. Moreover, the company's products are utilized in numerous fields: electronics, agriculture, and consumer goods, pointing to the versatility of bioinformatics microbial engineering (Chui et al., 2020).

6. Economic Impact of Biotechnology SMEs

Biotechnology SMEs stimulate innovation, craft jobs, and produce revenue which promotes economic growth. Their productivity is enhanced by incorporating bioinformatics in their business as it facilitates the emergence of new products and services. Biotechnology SMEs strengthen the economy in the following ways:

6.1. Innovation and Competitiveness

SMEs become capable of speedy and efficient innovations because of bioinformatics. This makes them retain a competitive edge in the biotech marketplace. Their innovative capabilities, enable them to fulfil various medical requirements by establishing easy-to-use diagnostic tools, novel medications, and effective therapies.

Advanced Research and Development (R&D): Bioinformatics tools not only automate data analysis, but also spot the drug targets, anticipate the biological responses, and as a result rationalize the R&D procedure. This speeds up the exploration and advancement of new products, it minimizes expenses of development and time-to-market. Though the resources of SMEs are restricted, the utilization of Bioinformatics tools optimizes the productivity of their research and speedily brings innovative solutions to the market (Lauer et al., 2021).

Customization and Precision: SMEs can set up customized products remarkably with the help of bioinformatics. A few examples of such customized products are personalized medicine and targeted therapies. SMEs can develop treatments according to the needs of patients by investigating genetic and molecular data. It makes patients satisfied by improving health outcomes. This customization and precision give competitive leverage to SMEs in the healthcare market (Lauer et al., 2021; Sunil Krishnan et al., 2021).

Collaborative Innovation: SMEs partner with academic institutions, and conglomerates with the assistance of Bioinformatics. SMEs can utilize collaborative research projects and shared data platforms to take advantage of external expertise and resources, which make the biotechnology ecosystem dynamic and innovative. Such collaborations of SMEs with academic institutions, and conglomerates cause discoveries and success (Lauer et al., 2021).

6.1.1. Case Example

Reflect on the changes that occurred in the vaccine development due to bioinformatics. The conventional techniques of generating vaccines are long, and energy-consuming. By applying bioinformatics, companies such as Moderna have been able to quickly develop and test potential vaccines which is evident in the modern world like the COVID-19 vaccine. The ability to innovate is therefore critical to the competitiveness of any firm in the biotechnology industry characterized by constantly emerging innovations.

6.2. Job Creation

Research, development, and manufacturing-related highly skilled jobs emerge because of the expansion of biotechnology SMEs. Economic expansion in regions and states benefits greatly through these highly skilled jobs.

High-Skilled Employment: Employees skilled in molecular biology, biochemistry, bioinformatics, and computational biology are mainly needed by Biotechnology SMEs. Biotechnology SMEs produce skilled employees, with the help of high-skilled employment opportunities, which is necessarily required by the biotechnology sector.

Regional Economic Development: Biotechnology SMEs captivate skilled individuals and investments by the number of investors and revolutionize the region's economy entirely. Regions where biotech companies are numerous become innovation centers, as researchers, scientists, and entrepreneurs contribute significantly to them. As a result, local businesses are triggered and the economy is boosted (Keinänen, 2022).

Training and Education: Biotechnology SMEs offer various training sessions for students and new researchers by collaborating with universities and research institutions. The academia-industry gap is filled by traineeships, internships, and collaborative research projects, as the next generation of biotech professionals is made ready (Luiz & Walter, 2023).

Case Example: Biotech hubs such as the San Francisco Bay Area and Boston have achieved their growth through hundreds of SMEs each generating many thousands of high-quality jobs. These areas, supported and profited by local governments along with educational institutions are poised to become thriving economic centers due to the advancing biotechnology industry here.

6.3. Revenue Generation

Proficient biotechnology SMEs market their products and services and produce revenue substantially. The generated revenue drives the innovation cycle as it is used to carry out advanced research and development.

Product Commercialization: Biotechnology SMEs are producers of pharmaceuticals and agricultural products, industrial biocatalysts, and diagnostic tests. Their product commercialization is economically profitable. Moreover, they fulfil the requirements related to healthcare, agriculture, and industry (Wakchaure et al., 2022).

Market Expansion: Using Bioinformatics makes entry to the global market for SMEs. Using data analytics and computational design, companies can customize their products to comply with regional regulations as well as market dynamics across geographies, opening new customer bases in the process and creating revenue opportunities. The ability to tap into a global network is valuable, especially for SMEs that want to expand and grow sustainably over the long term (on Science et al., 2020).

Investment Attraction: Biotech SMEs captivate investors because of their innovative potential. The investments of investors expand them. The cycle of invention, expansion, and investment continues.

Case Example: Biotechnology SMEs can produce revenue by establishing innovative products. Ginkgo Bioworks is its best example. Ginkgo has secured great investments by generating industry-specific microorganisms. This shows the economic influence of SMEs leveraging Bioinformatics.

7. Challenges and Opportunities

There are a lot of benefits of bioinformatics integration, but its adoption is somehow challenging for Biotechnology SMEs. A few challenges are mentioned below:

Cost and Resource Constraints: SMEs have limited budgets and cannot afford costly solutions. Putting bioinformatics into practice can be expansive for them at times. Moreover, affording high-performance computing resources and big data storage is difficult for them.

Data Management and Privacy: Data management in large amounts is difficult for SMEs as they need robust data management systems. Besides, while dealing with sensitive genetic information, ensuring data privacy is also challenging for them.

Regulatory Compliance: SMEs face time constraints and complexity while navigating the regulatory landscape for biotechnology products and services. To avert these challenges, SMEs must ensure compliance with regulations to avoid such challenges.

Although SMEs face numerous challenges while leveraging bioinformatics, bioinformatics brings several benefits and great chances of growth and success.

7.1. Future Trends in Biotechnology and Bioinformatics

New trends and technologies in the biotechnology and bioinformatics landscape are constantly unfolding. The industry is going to modify based on such emerging trends. A few are mentioned below:

The advancement in synthetic biology will inevitably lead to the creation of more complex and diverse biological systems and organisms and therefore a need for better bioinformatics methods.

Personalized medicine will remain a focal area of growth for bioinformatics in the future due to its essential role in determining genetic factors of disease and designing corresponding treatment plans.

Considering that biotechnology is becoming more reliant on big data, researchers will subsequently improve analytics tools to utilize the abundant data.

Genetic engineering and therapeutic development will be re-modelled due to CRISPR and other gene editing technologies and will be accompanied by bioinformatics for designing experiments and analysis.

Some advancements that the combination of AI, and machine learning with bioinformatics will facilitate include Improved data analysis, Predictive modelling, and Automation of highly elaborate tasks.

7.2. Future Recommendations

A few recommendations to increase the influence of bioinformatics on biotechnology SMEs are:

Research and development related to Bioinformatics require funds. Funds can be secured easily by the partnership of stakeholders with the government. So, partnerships between stakeholders and the government should be strengthened.

To back the expanding biotechnology SMEs' requirements, investment in bioinformatics infrastructure is necessary.

Organizations should train employees regarding emerging trends in bioinformatics. Institutions should educate future researchers by specialized bioinformatics courses.

SMEs can be more innovative at less cost if they have free access to bioinformatics tools, databases, and research findings so collaboration and data sharing should be boosted.

8. Conclusion

Thus, bioinformatics can become an effective opportunity to increase the success rate of SMEs in biotechnology. This paper demonstrates how bioinformatics could be instrumental in advancing SMEs' innovation, productivity, and the economy. Therefore, it is crucial to indicate that the prospects for growth and development in biotechnology are truly vast. In this scenario, as the market grows more competitive, the biotech SMEs that adopt bioinformatics shall be in a good place to compete and contribute toward scientific innovation and economic development.

Compliance with ethical standards

Disclosure of conflict of interest

No conflict of interest to be disclosed.

References

[1] Attwood, T. K., Blackford, S., Brazas, M. D., Davies, A., & Schneider, M. V. (2019). A global perspective on evolving bioinformatics and data science training needs. *Briefings in Bioinformatics, 20*(2), 398-404. https://doi.org/10.1093/bib/bbx100

[2] Barbier, A. J., Jiang, A. Y., Zhang, P., Wooster, R., & Anderson, D. G. (2022). The clinical progress of mRNA vaccines and immunotherapies. *Nature biotechnology, 40*(6), 840-854. https://doi.org/10.1038/s41587-022-01294-2

[3] Bloem, V., & Salimi, N. (2023). Role of knowledge management processes within different stages of technological innovation: evidence from biotechnology SMEs. *Knowledge Management Research & Practice, 21*(4), 822-836. https://doi.org/10.1080/14778238.2022.2064352

[4] Branco, I., & Choupina, A. (2021). Bioinformatics: new tools and applications in life science and personalized medicine. *Applied microbiology and biotechnology, 105*, 937-951. https://doi.org/10.1007/s00253-020-11056-2

[5] Cherchem, N., & Keen, C. (2022). International entrepreneurial ecosystem, knowledge exploitation and innovation: Case of international pharma-biotech SME. *The International Dimension of Entrepreneurial Decision-Making: Cultures, Contexts, and Behaviours*, 65-79. https://doi.org/10.1007/978-3-030-85950-3_4

[6] Chui, M., Evers, M., & Zheng, A. (2020). How the bio revolution could transform the competitive landscape. *McKinsey Quarterly, 7*.

[7] Coghlan, C., Labrecque, J., Ma, Y., & Dube, L. (2020). A biological adaptability approach to innovation for small and medium enterprises (SMEs): Strategic insights from and for health-promoting agri-food innovation. *Sustainability, 12*(10), 4227. https://doi.org/10.3390/su12104227

[8] CrISPr-based, P. Microsoft makes splash in AI-enabled lab solutions. https://doi.org/10.1038/d41587-019-00018-3

[9] Daniel, S., Kis, Z., Kontoravdi, C., & Shah, N. (2022). Quality by Design for enabling RNA platform production processes. *Trends in biotechnology, 40*(10), 1213-1228. https://doi.org/10.1016/j.tibtech.2022.03.012

[10] Demirer, G. S., Silva, T. N., Jackson, C. T., Thomas, J. B., W. Ehrhardt, D., Rhee, S. Y., Mortimer, J. C., & Landry, M. P. (2021). Nanotechnology to advance CRISPR–Cas genetic engineering of plants. *Nature Nanotechnology, 16*(3), 243-250. https://doi.org/10.1038/s41565-021-00854-y

[11] Dutton, G. (2021). Synthetic Biology Engineers the Next Genomic Revolution: Let information technology boast of killer apps—synthetic biology would rather assemble and program living apps. *Genetic Engineering & Biotechnology News, 41*(9), 42-45. https://doi.org/10.1089/gen.41.09.17

[12] Fernandez-Pozo, N., Haas, F. B., Gould, S. B., & Rensing, S. A. (2022). An overview of bioinformatics, genomics, and transcriptomics resources for bryophytes. *Journal of Experimental Botany, 73*(13), 4291-4305. https://doi.org/10.1093/jxb/erac052

[13] Gahlawat, A., Varma, T., Kamble, P., Banerjee, A., Sandhu, H., & Garg, P. (2023). Bioinformatics: Theory and Applications. In *The Quintessence of Basic and Clinical Research and Scientific Publishing* (pp. 539-555). Springer. https://doi.org/10.1007/978-981-99-1284-1_33

[14] Iansiti, M.A.R.C.O., Lakhani, K.M., Mayer, H. and Herman, K.E.R.R.Y., (2020). Moderna (A).

[15] [Record #1917 is using a reference type undefined in this output style.]

[16] Keinänen, S. (2022). *High-skilled immigrant entrepreneurs in the Finnish biotechnology sector: The social network perspective* Itä-Suomen yliopisto].

[17] Khan, F. A. (2020). *Biotechnology Fundamentals Third Edition*. CRC Press. https://doi.org/10.1201/9781003024750

[18] Kim, H. (2022). Open-source software for developing appropriate smart manufacturing technology for small and medium-sized enterprises (SMEs). *Journal of Appropriate Technology, 8*(3), 109-116.

[19] [Record #1909 is using a reference type undefined in this output style.]

[20] Kumar, H. K., Naveen, B., & Savitha, J. (2022). Business Factors Challenging SMEs for Adopting Cloud-Based Solutions. *International Journal of Global Business and Competitiveness, 17*(2), 203-214. https://doi.org/10.1007/s42943-022-00058-8

[21] Lakshmi, P., & Ramyachitra, D. (2020). Review about bioinformatics, databases, sequence alignment, docking, and drug discovery. *Statistical modelling and machine learning principles for bioinformatics techniques, tools, and applications*, 11-23. https://doi.org/10.1007/978-981-15-2445-5_2

[22] Lauer, K. B., Smith, A., Blomberg, N., Sitjà, X. P., Talbot-Cooper, C., Rothe, H., & Conde, D. S. (2021). Open data: a driving force for innovation in the life sciences. *F1000Research, 10*(828), 828. https://doi.org/10.7490/f1000research.1118745.1

[23] Levine, D. S. (2021). Foundational Tools for Building a New Bioeconomy. *Journal of Commercial Biotechnology, 26*(2), 52-55.

[24] Lord, M. (2018). DISRUDISRUPTING DNA. *ASEE Prism, 27*(6), 28-31.

[25] Luiz, A., & Walter, S. (2023). Identifying the determinants for biotechnology development (development will be studied through growth): highlighting the roles played by entrepreneurship education, entrepreneurial skills, and entrepreneurial attitude within the UK. *Journal of Commercial Biotechnology, 28*(3), 95-109. https://doi.org/10.5912/jcb2101

[26] Mahalakshmi, K., Kumar, A., Chouhan, A., & Rajammal, S. (2022). An Analysis of Bioinformatics Applications and Overview. *IJFANS Int. J. FOOD Nutr. Sci., 11*(3), 1220-1230.

[27] Mathias, J., Grediac, M., & Michaud, P. (2016). Biopolymers and Biotech Admixtures for Eco-Efficient Construction Materials (pp.369-385). https://doi.org/10.1016/B978-0-08-100214-8.00016-6

[28] Maurya, D. K., Kumar, A., Chaurasiya, U., Hussain, T., & Singh, S. K. (2021). Modern era of microbial biotechnology: opportunities and future prospects. In *Microbiomes and plant health* (pp. 317-343). Elsevier. https://doi.org/10.1016/B978-0-12-819715-8.00011-2

[29] Moderator:, Herrera, S., Panelists:, Shetty, R., Widmaier, D., & Dietrich, J. (2016). Young Stars in Industrial Biotechnology. *Industrial Biotechnology, 12*(3), 146-150. https://doi.org/10.1089/ind.2016.29036.she

[30] Morohoshi, N., & Komamine, A. (2001). *Molecular breeding of woody plants*. Elsevier.

[31] NHS. *Genomics Education Programme*. https://www.genomicseducation.hee.nhs.uk/education/core-concepts/what-is-bioinformatics/

[32] Nicholl, D. S. (2023). *An introduction to genetic engineering*. Cambridge University Press.

[33] Noor, R. (2021). Developmental Status of the Potential Vaccines for the Mitigation of the COVID-19 Pandemic and a Focus on the Effectiveness of the Pfizer-BioNTech and Moderna mRNA Vaccines. *Current clinical microbiology reports*, 1-8. https://doi.org/10.1007/s40588-021-00162-y

[34] on Science, B., National Academies of Sciences, E., & Medicine. (2020). ECONOMIC AND NATIONAL SECURITY RISKS PERTAINING TO THE BIOECONOMY. In *Safeguarding the Bioeconomy*. National Academies Press (US).

[35] Outeiral, C., Strahm, M., Shi, J., Morris, G. M., Benjamin, S. C., & Deane, C. M. (2021). The prospects of quantum computing in computational molecular biology. *Wiley Interdisciplinary Reviews: Computational Molecular Science, 11*(1), e1481. https://doi.org/10.1002/wcms.1481

[36] Poblete-Castro, I., Wittmann, C., & Nikel, P. I. (2020). Biochemistry, genetics and biotechnology of glycerol utilization in Pseudomonas species. *Microbial Biotechnology, 13*(1), 32-53. https://doi.org/10.1111/1751-7915.13400

[37] PRESSBOOKS. *SCIENCE, TECHNOLOGY, & SOCIETY: A STUDENT-LED EXPLORATION*. https://pressbooks.pub/anne1/chapter/personalized-medicine/

[38] Rasmussen, L., Sanders, S., Sosa, M., McKellip, S., Nebane, N. M., Martinez-Gzegozewska, Y., Reece, A., Ruiz, P., Manuvakhova, A., & Zhai, L. (2024). A high-throughput response to the SARS-CoV-2 pandemic. *SLAS Discovery*, 100160. https://doi.org/10.1016/j.slasd.2024.100160

[39] Rosales-Mendoza, S., García-Silva, I., González-Ortega, O., Sandoval-Vargas, J. M., Malla, A., & Vimolmangkang, S. (2020). The potential of algal biotechnology to produce antiviral compounds and biopharmaceuticals. *Molecules, 25*(18), 4049.

[40] Saeed, M. S., Saeed, A., Iqbal, M., & Adnan, M. (2020). Utilization of Bioinformatics in the Field of Biotechnology-A Review. *Int. J. Rec. Biotech, 8*(4), 16-18. https://doi.org/10.18782/2322-0392.1296

[41] Sarkar, A. A. (2021). Advances in Computational Biosciences Protocols. *Genetic Engineering & Biotechnology News, 41*(P1), P43-P45. https://doi.org/10.1089/gen.41.P1.15

[42] Sharma, R., Kaur, G., Bansal, P., Chawla, V., & Gupta, V. (2023). Bioinformatics paradigms in drug discovery and drug development. *Current topics in medicinal chemistry, 23*(7), 579-588. https://doi.org/10.2174/1568026623666221229113456

[43] Si, T., & Zhao, H. (2016). A brief overview of synthetic biology research programs and roadmap studies in the United States. *Synthetic and systems biotechnology, 1*(4), 258-264. https://doi.org/10.1016/j.synbio.2016.08.003

[44] [Record #1925 is using a reference type undefined in this output style.]

[45] Sunil Krishnan, G., Joshi, A., & Kaushik, V. (2021). Bioinformatics in personalized medicine. *Advances in Bioinformatics*, 303-315. https://doi.org/10.1007/978-981-33-6191-1_15

[46] Tan, X., Letendre, J. H., Collins, J. J., & Wong, W. W. (2021). Synthetic biology in the clinic: engineering vaccines, diagnostics, and therapeutics. *Cell, 184*(4), 881-898. https://doi.org/10.1016/j.cell.2021.01.017

[47] TENPENNY, D. S. COVID-19 mRNA Vaccines.

[48] Wakchaure, N., Chawla, R., & Arora, J. S. (2022). Entrepreneurship in healthcare biotechnology. In *Biotechnology in Healthcare* (pp. 343-353). Elsevier. https://doi.org/10.1016/B978-0-323-90042-3.00006-2

[49] Waltz, E. (2023). Small innovators advance microbes as alternatives to chemical crop sprays. *Nat. Biotechnol, 41*, 162-164. https://doi.org/10.1038/s41587-023-01670-6

[50] Wong, J. C., Alla, K. R., & Dominic, P. (2020). A Proposed framework for identifying the role of data science in handling future pandemics for Malaysian SMEs through technology acceptance model. 2020 International Conference on Computational Intelligence (ICCI),

[51] Wu, H. (2020). Community Partnerships for Enhanced Research Experience in Biomedical Informatics. 2020 IEEE Frontiers in Education Conference (FIE),

[52] Zeng, W., Guo, L., Xu, S., Chen, J., & Zhou, J. (2020). High-throughput screening technology in industrial biotechnology. *Trends in biotechnology, 38*(8), 888-906. https://doi.org/10.1016/j.tibtech.2020.01.001